Primary source: Manage a medical device supply disruption
The TGA has enhanced its enforcement operations against companies involved in the unlawful supply of vaping goods, leading to multiple seizures of illicit products and potential regulatory compliance impacts.
These actions significantly disrupt unlawful supply chains and reinforce compliance with therapeutic goods regulations, impacting public health and safety concerning vaping products.
Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.
The Therapeutic Goods Administration (TGA) has collaborated with the New South Wales Police Force and other enforcement agencies to disrupt the illicit importation and distribution of vaping goods and nicotine pouches. The operations led to the seizure of over 245,000 unlawful vaping products valued at more than $12.3 million, demonstrating a significant enforcement response to illegal vaping activities in New South Wales.
What changed: The TGA has enhanced its enforcement operations against companies involved in the unlawful supply of vaping goods, leading to multiple seizures of illicit products and potential regulatory compliance impacts.
Why it matters: These actions significantly disrupt unlawful supply chains and reinforce compliance with therapeutic goods regulations, impacting public health and safety concerning vaping products.
Practical implication: Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
